Intelligence Profile
Science
Mechanism of Action
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that works by stimulating the body's natural growth hormone production pathway. Based on the available evidence, tesamorelin functions through the following mechanisms:
Primary Mechanism:
Tesamorelin acts as a GHRH receptor agonist, binding to GHRH receptors in the anterior pituitary gland. This binding stimulates the release of endogenous growth hormone (GH) from pituitary somatotrophs, which then triggers the downstream growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
Physiological Effects:
The activated GH-IGF-1 pathway leads to several metabolic and physiological changes:
- Fat metabolism: Growth hormone stimulates lipolysis, particularly targeting visceral adipose tissue, which explains tesamorelin's observed effects on reducing abdominal fat accumulation
- Protein synthesis: The GH-IGF-1 axis promotes protein anabolism and muscle maintenance
- Metabolic regulation: Growth hormone influences glucose metabolism and overall energy homeostasis
Clinical Applications:
The evidence shows tesamorelin has been studied primarily in HIV-positive patients, where it addresses lipodystrophy-related visceral fat accumulation. Clinical trials have examined its effects on abdominal fat reduction, liver fat content, and physical function improvements.
Limitations of Current Evidence:
While the basic GHRH receptor mechanism is well-established, the specific molecular details of tesamorelin's binding affinity, receptor selectivity, and downstream signaling cascades are not fully detailed in the provided evidence. The clinical studies focus more on therapeutic outcomes rather than detailed mechanistic analysis.
Note: This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider for personalized treatment recommendations.